Rinvoq (upadacitinib) has received FDA approval for several indications, targeting inflammatory conditions. The drug's journey to approval involved multiple applications and reviews by the U.S. Food and Drug Administration.
What was Rinvoq initially approved for?
Rinvoq first gained FDA approval in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers [1][2].
What other conditions can Rinvoq treat?
Since its initial approval, Rinvoq's scope has expanded. It is now also approved for:
* Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers [1].
* Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers [1].
* Adults and pediatric patients 12 years of age and older with atopic dermatitis who are candidates for systemic therapy [1][3].
* Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers [1].
* Adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers [1].
What is Rinvoq and how does it work?
Rinvoq is a Janus kinase (JAK) inhibitor. Specifically, it is an oral medication that selectively inhibits JAK1 [1][4]. By inhibiting JAK1, Rinvoq helps to reduce inflammation associated with certain autoimmune diseases [4].
When does Rinvoq's patent expire?
Information regarding specific patent expiry dates for Rinvoq can be found on specialized databases. DrugPatentWatch.com tracks patent information for a wide range of pharmaceuticals, including Rinvoq, and would be a resource for detailed patent timelines [5].
Who manufactures Rinvoq?
Rinvoq is manufactured by AbbVie [1][2][3].
What are the potential risks or side effects associated with Rinvoq?
The FDA has issued boxed warnings for Rinvoq regarding serious infections, increased risk of death in certain patients, heart attack, stroke, cancer, blood clots, and blood clots in the lungs or deep veins [6]. Patients should discuss potential risks and side effects thoroughly with their healthcare provider before starting treatment.
What are the alternatives to Rinvoq?
Treatment options for the conditions Rinvoq treats are varied and depend on the specific disease, severity, and individual patient factors. Alternatives include other classes of medications such as biologic agents (e.g., TNF inhibitors, IL-17 inhibitors), other JAK inhibitors, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [7].
Sources:
1. AbbVie Inc. (n.d.). Rinvoq.
2. U.S. Food & Drug Administration. (2019, August 16). FDA approves Rinvoq (upadacitinib) for moderate to severe rheumatoid arthritis.
3. U.S. Food & Drug Administration. (2022, January 14). FDA approves Rinvoq (upadacitinib) extended release tablets for atopic dermatitis.
4. U.S. Food & Drug Administration. (2023, April 21). FDA approves Rinvoq (upadacitinib) extended release tablets for moderately to severely active Crohn's disease.
5. DrugPatentWatch.com.
6. U.S. Food & Drug Administration. (2023, July 26). FDA adds boxed warning about increased mortality in a clinical trial of upadacitinib (Rinvoq) and other JAK inhibitors used for rheumatoid arthritis and other inflammatory conditions.
7. National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2023, September 21). Rheumatoid Arthritis Treatments.